Cardiac Remodeling in Chronic Kidney Disease

Toxins (Basel). 2020 Mar 5;12(3):161. doi: 10.3390/toxins12030161.


Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality of life and survival. Current treatment options are highly inadequate. As kidney function declines, numerous metabolic pathways are disturbed. Kidney and heart functions are highly connected by organ crosstalk. Among others, altered volume and pressure status, ischemia, accelerated atherosclerosis and arteriosclerosis, disturbed mineral metabolism, renal anemia, activation of the renin-angiotensin system, uremic toxins, oxidative stress and upregulation of cytokines stress the sensitive interplay between different cardiac cell types. The fatal consequences are left-ventricular hypertrophy, fibrosis and capillary rarefaction, which lead to systolic and/or diastolic left-ventricular failure. Furthermore, fibrosis triggers electric instability and sudden cardiac death. This review focuses on established and potential pathophysiological cardiorenal crosstalk mechanisms that drive uremia-induced senescence and disease progression, including potential known targets and animal models that might help us to better understand the disease and to identify novel therapeutics.

Keywords: cardiac fibrosis; cardiorenal syndrome; chronic kidney disease; heart failure; left-ventricular hypertrophy; organ crosstalk; uremia; uremic cardiomyopathy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardio-Renal Syndrome* / drug therapy
  • Cardio-Renal Syndrome* / pathology
  • Disease Models, Animal
  • Humans
  • Renal Insufficiency, Chronic* / drug therapy
  • Renal Insufficiency, Chronic* / pathology
  • Ventricular Remodeling*